Publications by authors named "M Vandenhende"
Exposure to COVID-19 Pandemic-Related Stressors and Their Association With Distress, Psychological Growth and Drug Use in People With HIV in Nouvelle Aquitaine, France (ANRS CO3 AQUIVIH-NA Cohort-QuAliV-QuAliCOV Study).
AIDS Behav
January 2025
We investigated people living with HIV (PLWH)'s exposure to COVID-19 pandemic stressors and their association with distress, psychological growth, and substance use. PLWH in the ANRS CO3 AQUIVIH-NA cohort's QuAliV study (Nouvelle Aquitaine, France) completed an adapted CAIR Lab Pandemic Impact Questionnaire (C-PIQ) and reported substance use between 9/2021 to 3/2022. We described cumulative stressor exposure (score 0-16) and explored variation by PLWH characteristics (demographic, HIV-related, risk factors, psychosocial).
View Article and Find Full Text PDFArticle Synopsis
- This study examines central catheter-related bloodstream infections (CRBIs) at a tertiary care hospital over two years, focusing on complications caused by various bacteria, particularly Staphylococcus aureus (SA).
- Among 254 patients, 14% experienced complications such as suppurative thrombophlebitis and endocarditis, with risk factors including prolonged bacteremia, hemodialysis, and infections by SA.
- The findings suggest that patients with persistent bacteremia, especially those with SA and on hemodialysis, require thorough monitoring for potential complications to improve outcomes.
Background: Severe non-AIDS bacterial infections (SBIs) are among the leading causes of hospital admissions among persons with human immunodeficiency virus (PWH) in regions with high antiretroviral therapy coverage.
Methods: This large prospective cohort study of PWH examined the types of infections, bacterial documentation, and evolution of antibiotic resistance among PWH hospitalized with SBIs over an 18-year period.
Results: Between 2000 and 2017, 459 PWH had at least 1 SBI with bacterial documentation.
Background: The rationale behind the use of ethambutol in the standard tuberculosis treatment is to prevent the emergence of resistance to rifampicin in case of primary resistance to isoniazid. We evaluated whether early detection of isoniazid resistance using molecular testing allows the use an ethambutol-free regimen.
Methods: FAST-TB, a phase 4, French, multicenter, open-label, non-inferiority trial, compared 2 strategies: (1) polymerase chain reaction (PCR)-based detection of isoniazid and rifampicin resistance at baseline using Genotype MTBDR version 2.